Merck, Astellas and Pfizer bring down the house with Keytruda-Padcev FDA nod in bladder cancer

The combination therapy was hailed with a standing ovation in October at the European Society for Medical Oncology (ESMO) conference in Madrid. Less than two months later, the FDA has added its acclaim—blessing it five months ahead of its PDUFA date.